Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Shire buys Dyax for $5.5bn

Executive Summary

Shire PLC paid $5.5bn ($37.30 per share; a 36% premium) in cash to acquire Dyax Corp. Dyax shareholders may also receive a non-tradable contingent value right that will pay $4.00 in cash per share--about $646mm in total--upon approval (prior to the end of 2019) of its Phase III-ready plasma kallikrein (pKal) inhibitor DX2930 (lanadelumab) for prevention of Types 1 and 2 hereditary angioedema (HAE).

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Molecular Diversity
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Payment Includes Cash

Related Companies